CSOP Hang Seng HK-US TECH ETF(03442.HK) rose slightly 0.06% to HKD 8.600
Newtimespace News, as of 11:26 on May 11, CSOP Hang Seng HK-US TECH ETF(03442.HK) was quoted at HKD 8.600, up 0.06%. The ETF opened at HKD 8.595, with an intraday high of HKD 8.600 and a low of HKD 8.550. The latest NAV per unit is HKD 8.601, with a premium rate of 0.07%. The asset size is approximately HKD 645 million.
CSOP Hang Seng HK-US TECH ETF(03442.HK) tracks the Hang Seng Hong Kong-US Tech Index, which is compiled and published by Hang Seng Indexes Company Limited. The index aims to reflect the overall performance of large-cap technology companies listed in Hong Kong or the United States. By covering leading technology companies in both the Hong Kong and U.S. stock markets, the index achieves cross-market diversified allocation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HATCHER GROUP (08365.HK): Shareholder Buys Back 36% Stake in Target Company for HKD 1, Cutting Group's Stake to 15%; Target Signs Strategic Investment LOI for Low-Altitude Economy Project
- C HEALTH GP (08225.HK): Provides Update on Receivables Recovery; Applies to Set Aside Rejected Arbitration Award against Related Party, Collects RMB 2.088 Million from Cooperative Customers since June
- VGT (02476.HK): Third-Level Wholly-Owned Subsidiaries Sign Maximum Guarantee Agreements, Providing Mutual Guarantees of RMB 30 Million within Annual Guarantee Limit
- VIVA GOODS (00933.HK): Acquires Further 17,253,500 Li Ning Shares on Open Market for about HKD 228,207,000; Stake to Rise to about 17.58%
- OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China